Davidson & Garrard Inc. lessened its position in Johnson & Johnson (NYSE:JNJ) by 1.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 43,720 shares of the company’s stock after selling 779 shares during the quarter. Johnson & Johnson accounts for 1.3% of Davidson & Garrard Inc.’s portfolio, making the stock its 25th largest position. Davidson & Garrard Inc.’s holdings in Johnson & Johnson were worth $5,684,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in JNJ. OLD Point Trust & Financial Services N A increased its stake in Johnson & Johnson by 2.2% in the 2nd quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock worth $8,113,000 after buying an additional 1,321 shares during the period. Eagle Ridge Investment Management increased its stake in Johnson & Johnson by 3.5% in the 3rd quarter. Eagle Ridge Investment Management now owns 27,522 shares of the company’s stock worth $3,578,000 after buying an additional 928 shares during the period. Welch & Forbes LLC increased its stake in Johnson & Johnson by 0.9% in the 2nd quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock worth $95,028,000 after buying an additional 6,730 shares during the period. Janney Montgomery Scott LLC increased its stake in Johnson & Johnson by 0.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock worth $102,110,000 after buying an additional 3,533 shares during the period. Finally, Oliver Luxxe Assets LLC increased its stake in Johnson & Johnson by 12.7% in the 2nd quarter. Oliver Luxxe Assets LLC now owns 17,538 shares of the company’s stock worth $2,320,000 after buying an additional 1,972 shares during the period. Hedge funds and other institutional investors own 65.53% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) opened at $129.96 on Wednesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 12-month low of $115.32 and a 12-month high of $148.32. The stock has a market cap of $349,140.00, a P/E ratio of 333.23, a PEG ratio of 2.33 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The firm had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. During the same quarter in the previous year, the firm earned $1.58 EPS. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. research analysts forecast that Johnson & Johnson will post 8.08 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s payout ratio is currently 861.54%.
JNJ has been the topic of a number of research reports. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price on the stock in a research report on Thursday, January 11th. Citigroup raised their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. Stifel Nicolaus raised their target price on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Argus raised their target price on shares of Johnson & Johnson from $145.00 to $165.00 and gave the company a “positive” rating in a research report on Wednesday, October 18th. Finally, BMO Capital Markets raised their target price on shares of Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Johnson & Johnson has an average rating of “Hold” and an average target price of $146.16.
COPYRIGHT VIOLATION NOTICE: “Davidson & Garrard Inc. Has $5.68 Million Stake in Johnson & Johnson (JNJ)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/14/davidson-garrard-inc-has-5-68-million-stake-in-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.